Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Thalassemia × fludarabine phosphate × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 14 Lymphoma 13 Lymphoma, Mantle-Cell 12 Lymphoma, Follicular 12 Leukemia, Myeloid, Acute 12 Multiple Myeloma 11 Leukemia, Lymphocytic, Chronic, B-Cell 11 Leukemia 11 Burkitt Lymphoma 11 Lymphoma, Non-Hodgkin 10 Lymphoma, Large B-Cell, Diffuse 10 Hodgkin Disease 10 Congenital Abnormalities 10 Myeloproliferative Disorders 9 Lymphoma, Large-Cell, Immunoblastic 9 Lymphoma, B-Cell, Marginal Zone 9 Leukemia, Myeloid, Chronic-Phase 9 Leukemia, Myeloid, Accelerated Phase 9 Primary Myelofibrosis 8 Myelodysplastic Syndromes 8 Dendritic Cell Sarcoma, Interdigitating 8 Recurrence 7 Lymphoma, T-Cell, Cutaneous 7 Blast Crisis 7 Leukemia, Myelomonocytic, Juvenile 6 Sezary Syndrome 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5 Mycosis Fungoides 5 Leukemia, Myelomonocytic, Chronic 5 Anemia, Refractory, with Excess of Blasts 5

Interventions

fludarabine phosphate 1 fludarabine 1 Mesna 1 Cyclophosphamide 1 Busulfan 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡